PALB2 and ovarian carcinoma: Four patients had confirmed PR (3 patients with breast and 1 with ovarian cancer) (ORR 4/40 = 10%, 95% CI: 2.8–23.7); all patients with PR had germline DNA-repair abnormalities (2 BRCA2, 1 PALB2, 1 TP53 (with a concurrent BRCA2 VUS) (Figs. 2, 3).